Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.38 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.38 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988268 | 0.86 | ALDH1A1 (0.43) | CYP17A1BRAFNPC1KMT2AKCNQ4 | |
| SCHEMBL2988271 | 0.86 | ALDH1A1 (0.43) | CYP17A1BRAFNPC1KMT2AKCNQ4 | |
| SCHEMBL13247945 | 0.86 | ALDH1A1 (0.43) | CYP17A1BRAFNPC1KMT2AKCNQ4 | |
| SCHEMBL12479648 | 0.84 | USP30 (0.44) | CYP17A1PDE4BNPC1USP30HRH3 | |
| SCHEMBL12478772 | 0.82 | NAMPT (0.53) | PDE4BUSP30HRH3BTK | |
| SCHEMBL2493672 | 0.81 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DBRAF | |
| SCHEMBL27949193 | 0.81 | CYP17A1 (0.41) | CYP17A1BRAFMAPK14USP30HRH3 | |
| SCHEMBL5868762 | 0.80 | AAK1 (0.51) | CYP17A1DGAT1AAK1 | |
| SCHEMBL30118378 | 0.80 | AAK1 (0.51) | CYP17A1DGAT1AAK1 | |
| SCHEMBL13247990 | 0.80 | HRH3 (0.44) | NPC1RAB9AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379516-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND THEIR USES TO TREAT DIABETES | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20100184813-A1 | CHEMICAL COMPOUNDS 553 | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| WO-2010070343-A1 | 1,3,4-OXADIAZOLE DERIVATIVES AND THEIR USES TO TREAT DIABETES | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184813-A1 | CHEMICAL COMPOUNDS 553 | GCGR, DGAT1, GPBAR1 | CYP17A1 294/4885PDE4A 2862/4885PDE4B 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.